Inhibikase Therapeutics, Inc. - Common Stock (IKT)
2.3000
-0.0400 (-1.71%)
Inhibikase Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly those related to Parkinson's disease
The company aims to address the underlying mechanisms of these conditions by harnessing its proprietary drug discovery platform to identify and develop compounds that can improve patient outcomes. Their research is centered around the modulation of key biological pathways implicated in neurodegeneration, with the goal of offering new treatment options that can enhance the quality of life for individuals affected by these debilitating disorders.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 --
Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing.
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results.
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock at a combined purchase price of $1.68. The Series A and Series B warrants will each have an exercise price of $1.68 per share, will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the one-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the five-year anniversary from the date of stockholder approval.
